MCID: HYP070
MIFTS: 43

Hyperpituitarism

Categories: Endocrine diseases

Aliases & Classifications for Hyperpituitarism

MalaCards integrated aliases for Hyperpituitarism:

Name: Hyperpituitarism 12 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2444
MeSH 44 D006964
UMLS 73 C0020506

Summaries for Hyperpituitarism

MalaCards based summary : Hyperpituitarism is related to hyperthyroidism and hypopituitarism. An important gene associated with Hyperpituitarism is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are TGF-Beta Pathway and Peptide ligand-binding receptors. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and brain, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 76 Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones, it typically... more...

Related Diseases for Hyperpituitarism

Diseases related to Hyperpituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 hyperthyroidism 28.1 GH1 INS PRL SST TRH
2 hypopituitarism 26.4 GH1 GHRH IGF1 IGFBP3 INS POMC
3 galactorrhea 10.7 IGF1 PRL
4 glucagonoma 10.7 GHRH SST
5 prolactin producing pituitary tumor 10.7 PRL SST
6 bronchus adenoma 10.6 POMC SST
7 pancreatic cholera 10.6 GHRH SST
8 generalized resistance to thyroid hormone 10.6 PRL TRH
9 zollinger-ellison syndrome 10.5 GHRH SST
10 fasting hypoglycemia 10.5 IGF1 POMC
11 slipped capital femoral epiphysis 10.5 IGF1 IGFBP3
12 suprasellar meningioma 10.5 POMC TRH
13 acth-secreting pituitary adenoma 10.5 POMC PRL
14 diffuse idiopathic skeletal hyperostosis 10.5 IGF1 IGFBP3
15 fibrous dysplasia/mccune-albright syndrome 10.5 GH1 PRL
16 central precocious puberty 10.5 IGF1 IGFBP3
17 carcinoid syndrome 10.4 GHRH IGF1 SST
18 multiple endocrine neoplasia, type iv 10.4 AIP PRL
19 acid-labile subunit deficiency 10.4 IGF1 IGFBP3
20 acidophil adenoma 10.4 IGF1 POMC SST
21 diabetes insipidus, neurohypophyseal 10.4 POMC PRL
22 lymphocytic hypophysitis 10.3 GH1 POMC
23 ectopic cushing syndrome 10.3 POMC SST
24 persistent fetal circulation syndrome 10.3 IGF1 POMC
25 hormone producing pituitary cancer 10.3 AIP IGF1 SST
26 hypoadrenalism 10.3 GH1 POMC
27 central nervous system organ benign neoplasm 10.3 IGF1 POMC PRL
28 chiasmal syndrome 10.3 POMC PRL SST
29 pituitary carcinoma 10.3 POMC PRL SST
30 nelson syndrome 10.3 POMC PRL SST
31 adrenal cortex disease 10.2 POMC PRL SST
32 adrenal gland disease 10.2 POMC PRL SST
33 sella turcica neoplasm 10.2 GHRH POMC PRL
34 tuberculum sellae meningioma 10.2 GHRH POMC PRL
35 growth hormone secreting pituitary adenoma 10.2 AIP PRL SST
36 premenstrual tension 10.2 POMC PRL
37 tetrahydrobiopterin deficiency 10.2 GH1 PRL
38 acromesomelic dysplasia, maroteaux type 10.2 GHR IGF1
39 marasmus 10.1 GH1 IGFBP3
40 tsh producing pituitary tumor 10.1 GH1 PRL SST
41 mammographic density 10.1 IGF1 IGFBP3 PRL
42 amenorrhea 10.1 POMC PRL TRH
43 duodenal somatostatinoma 10.1 INS SST
44 breast disease 10.1 IGF1 IGFBP3 PRL
45 postgastrectomy syndrome 10.1 INS SST
46 postural hypotension 10.1 INS SST
47 hyperinsulinemic hypoglycemia, familial, 2 10.1 INS SST
48 donohue syndrome 10.0 IGF1 INS
49 graves' disease 10.0
50 somatostatinoma 10.0 INS SST

Graphical network of the top 20 diseases related to Hyperpituitarism:



Diseases related to Hyperpituitarism

Symptoms & Phenotypes for Hyperpituitarism

MGI Mouse Phenotypes related to Hyperpituitarism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.06 TRH IGF1 PRL IGFBP3 AIP INS
2 growth/size/body region MP:0005378 10.02 TRH GHRH IGF1 SST IGFBP3 AIP
3 homeostasis/metabolism MP:0005376 10.02 TRH IGF1 PRL SST IGFBP3 AIP
4 adipose tissue MP:0005375 9.83 POMC IGF1 IGFBP3 INS GHR
5 integument MP:0010771 9.8 IGF1 PRL IGFBP3 AIP INS GHR
6 liver/biliary system MP:0005370 9.7 PRL IGFBP3 AIP INS GHR POMC
7 nervous system MP:0003631 9.56 TRH POMC GHRH IGF1 PRL SST
8 renal/urinary system MP:0005367 9.02 POMC IGF1 IGFBP3 INS GHR

Drugs & Therapeutics for Hyperpituitarism

Drugs for Hyperpituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
4
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 383414 6400441
5
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
6 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
7
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
8
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Zinc Approved, Investigational Phase 4 7440-66-6 23994
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
14
Polyestradiol phosphate Approved Phase 4 28014-46-2
15
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
16 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
18 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
20 Dopamine D2 Receptor Antagonists Phase 4
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Paliperidone Palmitate Phase 4
23 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
24 Serotonin 5-HT2 Receptor Antagonists Phase 4
25 Serotonin Agents Phase 4,Phase 3,Not Applicable
26 Serotonin Antagonists Phase 4,Phase 3,Not Applicable
27 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 insulin Phase 4,Phase 3,Phase 2,Not Applicable
31 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
32 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
33 Complement Factor I Phase 4,Phase 3
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
38 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Protective Agents Phase 4,Phase 1,Phase 2
40 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Autonomic Agents Phase 4,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
43 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable
44 Dipeptidyl-Peptidase IV Inhibitors Phase 4
45 HIV Protease Inhibitors Phase 4
46 Incretins Phase 4
47
protease inhibitors Phase 4
48 Sitagliptin Phosphate Phase 4
49 Liver Extracts Phase 4
50 Estradiol 17 beta-cypionate Phase 4

Interventional clinical trials:

(show top 50) (show all 199)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
2 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
5 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
7 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
8 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
9 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
10 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
11 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
12 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
13 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
14 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
15 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
16 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
17 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
18 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
19 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
20 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
21 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
22 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
23 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
24 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
25 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
26 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
27 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
28 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
29 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
30 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
31 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
32 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
33 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
34 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
35 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
36 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
37 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
38 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
39 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
40 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
41 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
42 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
43 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
44 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
45 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
46 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
47 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
48 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
49 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
50 Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)

Search NIH Clinical Center for Hyperpituitarism

Cochrane evidence based reviews: hyperpituitarism

Genetic Tests for Hyperpituitarism

Anatomical Context for Hyperpituitarism

MalaCards organs/tissues related to Hyperpituitarism:

41
Pituitary, Bone, Brain, Testes, Skeletal Muscle, Liver, Heart

Publications for Hyperpituitarism

Articles related to Hyperpituitarism:

# Title Authors Year
1
Hyperpituitarism ( 29489207 )
2018
2
Congenital hyperpituitarism of hypothalamic origin: a new diencephalic syndrome with endocrine manifestations. ( 14444640 )
1959
3
Psychological findings in a case of von Recklinghausen's disease and hyperpituitarism. ( 13367234 )
1956
4
Further evidence that hyperthyroidism (Graves' disease) is not hyperpituitarism: effects of triiodothyronine and sodium iodide. ( 14367487 )
1955
5
Graves' disease: hyperthyroidism or hyperpituitarism. ( 13022743 )
1952
6
Creatine-creatinine metabolism in adult and juvenile hyperpituitarism. ( 18877070 )
1948
7
Hyperpituitarism and Hypopituitarism. ( 19312151 )
1940
8
Thyrotoxicosis with Unilateral Exophthalmos, Hyperpituitarism, and Infantile Hemiplegia. ( 19990197 )
1935
9
Case of Hyperpituitarism. ( 19984234 )
1925

Variations for Hyperpituitarism

Expression for Hyperpituitarism

Search GEO for disease gene expression data for Hyperpituitarism.

Pathways for Hyperpituitarism

Pathways related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.15 GH1 GHR GHRH IGF1 INS PRL
2
Show member pathways
13.13 GH1 GHR GHRH POMC PRL SST
3
Show member pathways
12.59 GH1 GHR IGF1 INS PRL
4
Show member pathways
12.47 GH1 GHR IGF1 PRL
5
Show member pathways
12.43 GH1 GHR IGF1 IGFBP3 INS
6 11.75 GH1 IGF1 INS
7 11.61 IGF1 IGFBP3 INS
8
Show member pathways
11.52 GH1 IGF1 INS POMC
9 11.14 GH1 GHR IGF1
10 11.09 IGF1 INS
11
Show member pathways
10.99 POMC TRH
12 10.82 IGF1 IGFBP3
13
Show member pathways
10.41 GH1 GHR PRL

GO Terms for Hyperpituitarism

Cellular components related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 GH1 GHR GHRH IGF1 IGFBP3 INS
2 insulin-like growth factor ternary complex GO:0042567 9.37 IGF1 IGFBP3
3 endosome lumen GO:0031904 9.33 GH1 INS PRL
4 insulin-like growth factor binding protein complex GO:0016942 9.32 IGF1 IGFBP3
5 extracellular region GO:0005576 9.32 GH1 GHR GHRH IGF1 IGFBP3 INS
6 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 GHRH IGF1 INS PRL
2 positive regulation of MAPK cascade GO:0043410 9.78 IGF1 IGFBP3 INS
3 cellular protein metabolic process GO:0044267 9.78 IGF1 IGFBP3 INS PRL
4 cell-cell signaling GO:0007267 9.77 GHRH INS POMC SST TRH
5 activation of MAPK activity GO:0000187 9.75 GHR IGF1 INS
6 glucose homeostasis GO:0042593 9.73 IGF1 INS POMC
7 response to glucose GO:0009749 9.71 IGF1 INS TRH
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 GH1 IGF1 INS
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 GH1 GHR IGF1
10 activation of protein kinase B activity GO:0032148 9.64 IGF1 INS
11 positive regulation of glucose import GO:0046326 9.63 IGF1 INS
12 positive regulation of multicellular organism growth GO:0040018 9.63 GH1 GHR GHRH
13 positive regulation of mitotic nuclear division GO:0045840 9.62 IGF1 INS
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.62 GH1 GHR IGF1 INS
15 response to food GO:0032094 9.61 GHR GHRH
16 regulation of multicellular organism growth GO:0040014 9.61 GHR IGF1 PRL
17 positive regulation of glycolytic process GO:0045821 9.6 IGF1 INS
18 positive regulation of insulin receptor signaling pathway GO:0046628 9.59 IGF1 INS
19 positive regulation of glycogen biosynthetic process GO:0045725 9.58 IGF1 INS
20 positive regulation of JAK-STAT cascade GO:0046427 9.58 GH1 GHR PRL
21 insulin-like growth factor receptor signaling pathway GO:0048009 9.57 GHR IGF1
22 growth hormone receptor signaling pathway GO:0060396 9.55 GH1 GHR
23 negative regulation of feeding behavior GO:2000252 9.52 INS TRH
24 response to nutrient levels GO:0031667 9.46 GH1 IGF1 INS PRL
25 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.43 GH1 GHR PRL
26 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
27 regulation of signaling receptor activity GO:0010469 9.23 GH1 GHRH IGF1 INS POMC PRL
28 G-protein coupled receptor signaling pathway GO:0007186 10.03 GHRH INS POMC SST TRH

Molecular functions related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.32 IGF1 INS
2 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS
3 hormone activity GO:0005179 9.17 GH1 IGF1 INS POMC PRL SST
4 receptor activator activity GO:0030546 9.16 IGF1 INS
5 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperpituitarism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....